Lonza Starts Construction on New $218-M Small-Molecule Mfg ComplexBy
Lonza has started construction on a new CHF 200-million ($218-million) small-molecule manufacturing complex at its site in Visp, Switzerland.
The new manufacturing complex will occupy an overall footprint of approximately 2000 m2 with six levels of manufacturing space. The complex will allow for future expansions supporting small-molecules technologies, including for drug substances, particle engineering, such as spray-drying dispersions, and drug products.
This construction project is supported by a capital contribution and a long-term collaboration with an undisclosed bio/pharmaceutical partner.
The first build-out represents a customer-dedicated manufacturing line for antibody-drug conjugate payload molecules, which is expected to start its first operations in the third quarter of 2023. Upon completion, the manufacturing complex will employ approximately 200 people.